Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention

被引：90

作者：

Bohnacker, Thomas ^{[1
]}

Prota, Andrea E. ^{[2
]}

Beaufils, Florent ^{[1
,7
]}

Burke, John E. ^{[3
]}

Melone, Anna ^{[1
]}

Inglis, Alison J. ^{[4
]}

Rageot, Denise ^{[1
]}

Sele, Alexander M. ^{[1
]}

Cmiljanovic, Vladimir ^{[1
,7
]}

Cmiljanovic, Natasa ^{[1
,7
]}

Bargsten, Katja ^{[2
,9
]}

Aher, Amol ^{[5
]}

Akhmanova, Anna ^{[5
]}

Fernando Diaz, J. ^{[6
]}

Fabbro, Doriano ^{[7
]}

Zvelebil, Marketa ^{[8
]}

Williams, Roger L. ^{[4
]}

Steinmetz, Michel O. ^{[2
]}

Wymann, Matthias P. ^{[1
]}

机构：

[1] Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland

[2] Paul Scherrer Inst, Dept Biol & Chem, Lab Biomol Res, CH-5232 Villigen, Switzerland

[3] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 2Y2, Canada

[4] MRC Lab Mol Biol, Cambridge CB2 2QH, England

[5] Univ Utrecht, Cell Biol, Fac Sci, NL-3584 CH Utrecht, Netherlands

[6] CIB Ctr Invest Biol, Madrid 28040, Spain

[7] PIQUR Therapeut AG, CH-4057 Basel, Switzerland

[8] Inst Canc Res, London SW3 6JB, England

[9] Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland

来源：

NATURE COMMUNICATIONS | 2017年 / 8卷

基金：

瑞士国家科学基金会;

关键词：

METASTATIC BREAST-CANCER; ADVANCED SOLID TUMORS; IN-VITRO; PI3-KINASE INHIBITOR; KINASE INHIBITOR; DOSE-ESCALATION; CELL-DEATH; PHASE-I; NVP-BKM120; BKM120;

D O I：

10.1038/ncomms14683

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization. Here, we developed two chemical derivatives that differ from BKM120 by only one atom. We show that these minute changes separate the dual activity of BKM120 into discrete PI3K and tubulin inhibitors. Analysis of the compounds cellular growth arrest phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K. Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide insights into the selective mode of action of this class of drugs. Our results raise concerns over BKM120's generally accepted mode of action, and provide a unique mechanistic basis for next-generation PI3K inhibitors with improved safety profiles and flexibility for use in combination therapies.

引用

页数：13

共 50 条

[31] β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells
Yi, Yong Weon
Kang, Hyo Jin
Bae, Edward Jeong
Oh, Seunghoon
Seong, Yeon-Sun
Bae, Insoo
EXPERIMENTAL AND MOLECULAR MEDICINE, 2015, 47 : e143 - e143
[32] β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells
Yong Weon Yi
Hyo Jin Kang
Edward Jeong Bae
Seunghoon Oh
Yeon-Sun Seong
Insoo Bae
Experimental & Molecular Medicine, 2015, 47 : e143 - e143
[33] Action mechanisms and structure-activity relationships of PI3Kγ inhibitors on the enzyme:: a molecular modeling study
Kuang, R. -R.
Qian, F.
Li, Z.
Wei, D. -Z.
Tang, Y.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2006, 41 (04) : 558 - 565
[34] The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines
Ma, Yixuan
Sender, Sina
Sekora, Anett
Kong, Weibo
Bauer, Peter
Ameziane, Najim
Al-Ali, Ruslan
Krake, Susann
Radefeldt, Mandy
Weiss, Frank Ulrich
Lerch, Markus M.
Parveen, Alisha
Zechner, Dietmar
Junghanss, Christian
Escobar, Hugo Murua
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (08)
[35] Isoform-Specific Inhibitors of PI3K Impair Agonist-Induced Ca2+ Signaling in a PI3K-Independent Manner
Dymova, E. A.
Rogachevskaja, A.
Kotova, P. D.
BIOLOGICHESKIE MEMBRANY, 2022, 39 (06): : 440 - 445
[36] Comparative cancer cell line profiling differentiates the mechanism of action of different PI3K/mTOR, Aurora kinase and EZH2 inhibitors
Uitdehaag, Joost C. M.
de Roos, Jeroen A. D. M.
Prinsen, Martine B. W.
de Vetter, Judith R. F.
Dylus, Jelle
van Doornmalen, Antoon M.
van Gerwen, Suzanne J. C.
de Man, Jos
Buijsman, Rogier C.
Zaman, Guido J. R.
CANCER RESEARCH, 2016, 76
[37] Interplay between PI3k/AKT signaling and caspase pathway in Alzheimer disease: mechanism and therapeutic implications
Bhatia, Vandana
Vikram, Vir
Chandel, Anjali
Rattan, Aditya
INFLAMMOPHARMACOLOGY, 2025, : 1785 - 1802
[38] Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors
Qian, Xiao-jun
Li, Yun-tian
Yu, Yan
Yang, Fen
Deng, Rong
Ji, Jiao
Jiao, Lin
Li, Xuan
Wu, Rui-Yan
Chen, Wen-Dan
Feng, Gong-Kan
Zhu, Xiao-Feng
ONCOTARGET, 2015, 6 (07) : 5134 - 5146
[39] Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP
Mentes, Muratcan
Karakuzulu, Basak Buse
Ucar, Gonlum Bahar
Yandim, Cihangir
COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2022, 99
[40] NOVEL PI3K/P110BETA-SPECIFIC INHIBITORS ELIMINATE ENZALUTAMIDE RESISTANCE IN PROSTATE CANCER
Austenfeld, Marcus
He, Chenchen
Wang, Yifen
Hu, Qingting
Thrasher, Brantley
Li, Benyi
JOURNAL OF UROLOGY, 2016, 195 (04): : E761 - E761

← 1 2 3 4 5 →